Biocon will supply a range of insulin products in Malaysia after its long-time partner, Duopharma Biotech Berhad, secured multiple government contracts from the country’s Ministry of Health valued at more than MYR 225 million.
Biocon Ltd. has strengthened its presence in Malaysia’s diabetes care market after its long-standing partner, Duopharma Biotech Berhad, won several insulin supply contracts from Malaysia’s Ministry of Health (MoH) with a combined value exceeding MYR 225 million.
Under the agreements announced on June 24, Biocon’s Malaysian subsidiary, Biocon Sdn. Bhd., will manufacture and supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad, which will distribute the medicines across the country’s public healthcare system.
The contracts include a three-year agreement worth approximately MYR 155.27 million for human insulin, along with two separate two-year contracts valued at around MYR 18 million for insulin glargine and MYR 52.5 million for insulin aspart.
Biocon said Malaysia has played a significant role in its insulin manufacturing operations for more than a decade, with its integrated facility in Johor serving both domestic and international markets. The company said the latest contracts would support continued access to affordable insulin therapies for patients while ensuring a stable supply of essential medicines.
According to the company, the partnership with Duopharma Biotech began in 2016 to address Malaysia’s growing diabetes burden. Over the past decade, the collaboration has supplied more than 120 million insulin cartridges to Ministry of Health facilities, benefiting over 450,000 patients within the country’s public healthcare system.
The companies also noted that their collaboration extends beyond diabetes care. In addition to working together in oncology for more than seven years, they have recently expanded their partnership into ophthalmology biologics to improve access to biologic medicines in Malaysia.
Malaysia is estimated to have around 4.75 million people living with diabetes, highlighting the continued demand for reliable insulin supplies. Biocon said the latest agreements align with the country’s healthcare and industrial development plans aimed at strengthening domestic pharmaceutical capabilities and ensuring continued availability of essential medicines.
